Italy's Health Triage adds €3M for its AI cancer-screening tools
What's the deal? Italian deeptech Health Triage has raised €3 million in an early-VC round from Vertis SGRDealroom has a profile for this one. Try Dealroom → — through its Vertis Venture 6 Digital Sud fund — and Health 1. The Turin-founded company builds artificial intelligence tools for cancer prevention.
Why now? The raise follows a €5 million investment closed in 2025 by Fondazione ENEA Tech e BiomedicalDealroom has a profile for this one. Try Dealroom →, an entity overseen by Italy's ministries of enterprise and health. The new capital consolidates Health Triage's growth path rather than opening a new chapter.
What's the endgame? Founded as a startup in 2020, Health Triage completed incubation at I3PDealroom has a profile for this one. Try Dealroom →, the Polytechnic University of Turin's incubator, in 2023. It is controlled by the Fin Posillipo group and develops two proprietary tools, BreastNegative and Prostate V-Bio.
The money will fund organic development of its portfolio, continuous clinical validation, and integration into hospital workflows. The goal, the company says, is to turn AI into a daily clinical standard for early diagnosis.
What they're saying: The round is "a fundamental step in Health Triage's consolidation path," said founder and chief executive officer Davide Dettori. Renato Vannucci, partner and vice president at Vertis SGRDealroom has a profile for this one. Try Dealroom →, called the company "a concrete example of how artificial intelligence can generate real impact in the clinical field."
What could go wrong? The tools still need continuous clinical validation and adoption inside hospital systems — a slow process. Health Triage is also leaning on repeated backing from a small circle of Italian institutional investors rather than broad international capital.
The signal: The deal matters less for its size than for confirming staged, sustained funding behind a single national champion in AI oncology. That stands out at a time when many early-stage European health-AI startups struggle to secure follow-on capital.
Read more: I3P
Image credit: NavyMedicine
